期刊
NATURE MEDICINE
卷 22, 期 5, 页码 472-478出版社
NATURE PORTFOLIO
DOI: 10.1038/nm.4091
关键词
-
资金
- US National Institutes of Health Director's Office and Common Fund [DP2-CA174497]
- National Cancer Institute [R01-CA169338]
- HHMI Collaborative Innovation Award Program
- Searle Scholars Program
- Pew Charitable Trust
- Addario Lung Cancer Foundation
- V Foundation for Cancer Research
- University of Colorado Lung Cancer SPORE
Molecular targeted therapy has the potential to dramatically improve survival in patients with cancer. However, complete and durable responses to targeted therapy are rare in individuals with advanced-stage solid cancers. Even the most effective targeted therapies generally do not induce a complete tumor response, resulting in residual disease and tumor progression that limits patient survival. We discuss the emerging need to more fully understand the molecular basis of residual disease as a prelude to designing therapeutic strategies to minimize or eliminate residual disease so that we can move from temporary to chronic control of disease, or a cure, for patients with advanced-stage solid cancers. Ultimately, we propose a shift from the current reactive paradigm of analyzing and treating acquired drug resistance to a pre-emptive paradigm of defining the mechanisms that result in residual disease, to target and limit this disease reservoir.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据